Physician profile
Robert Coffee
NPI 1558475582
$11,825.52
in general payments reported to CMS, 2019-2025
24 companies · $971 in 2025
The $971 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,417 · 2020: $106 · 2021: $355 · 2022: $1,524 · 2023: $1,147 · 2024: $2,306 · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,581 · Travel and Lodging: $802 · Education: $40.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,581.22 |
| Travel and Lodging | $802.36 |
| Education | $40.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $5,171.15 | 2019-2024 | Iluvien, Yutiq |
| Eyepoint US, INC. | $1,545.80 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $1,198.44 | 2020-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $669.07 | 2020-2025 | Acthar |
| Genentech USA, INC. | $609.81 | 2022-2025 | Vabysmo, Susvimo |
| Alcon Vision LLC | $368.63 | 2021-2025 | Constellation, Rocklatan |
| Abbvie INC. | $326.35 | 2022-2024 | Ozurdex, Durysta, Lumigan |
| Microsurgical Technology, INC. | $237.92 | 2025 | |
| Coopervision INC. | $214.49 | 2022-2023 | Myday Contact Lens |
| Allergan, INC. | $204.71 | 2019-2020 | |
| Astellas Pharma US INC | $192.74 | 2023-2025 | Izervay |
| Regeneron Pharmaceuticals, INC. | $184.17 | 2022-2025 | Eylea Hd |
| Carl Zeiss Meditec USA, INC. | $178.63 | 2024 | |
| Beaver-Visitec International, INC. | $176.62 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $142.61 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $86.31 | 2022 | |
| Dutch Ophthalmic, USA | $77.04 | 2022 | |
| Ani Pharmaceuticals, INC. | $50.24 | 2024 | Purified Cortrophin Gel |
| Sun Pharmaceutical Industries INC. | $47.15 | 2020-2024 | |
| Apellis Pharmaceuticals, INC. | $44.55 | 2023 | Syfovre |
| Harrow Eye, LLC | $35.50 | 2023-2024 | Iheezo |
| Medtronic, INC. | $28.98 | 2025 | Valleylab Ft10 |
| Coherus Oncology, INC. | $18.87 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $15.74 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Coffee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.